KURA Kura Oncology, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1422143 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-35.0%
TTM EPS YoY-33.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-394.3%
Net margin-369.3%
FCF margin-112.4%
EBITDA margin-392.5%
Returns
ROE-224.9%
ROA-48.2%
ROIC (approx.)-389.8%
Asset turnover0.13x
Leverage & solvency
Liabilities / assets96.8%
Debt / equity0.55x
Current ratio3.60x
Interest coverage-227.12x
Cash quality & payout
Operating cash flow / net income0.29x
Accruals ratio-34.1%
Payout ratio—
Capex / revenue4.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $67.48M | $53.88M |
| R&D expense | $251.07M | $169.97M |
| SG&A expense | $119.98M | $77.11M |
| Operating income | -$303.63M | -$193.19M |
| Interest expense | $1.51M | $1.62M |
| Pretax income | -$278.37M | -$171.97M |
| Income tax | $297,000 | $2.02M |
| Net income | -$278.67M | -$173.98M |
| EBITDA | -$302.60M | -$192.35M |
| EPS (basic) | -3.18 | -2.02 |
| EPS (diluted) | -3.18 | -2.02 |
| Weighted avg. shares (diluted) | 87.68M | 86.16M |
| Balance sheet | ||
| Cash & equivalents | $149.10M | $224.46M |
| Short-term investments | $518.14M | $502.93M |
| Receivables | $8.80M | $2.06M |
| Inventory | $413,000 | $0 |
| Current assets | $708.66M | $744.83M |
| PP&E, net | $7.86M | $1.68M |
| Total assets | $738.36M | $760.16M |
| Current liabilities | $116.97M | $78.71M |
| Short-term debt | $0 | $2.61M |
| Long-term debt | $9.71M | $6.92M |
| Total debt | $9.71M | $9.52M |
| Total liabilities | $564.23M | $346.52M |
| Shareholders' equity | $174.13M | $413.64M |
| Net debt | -$139.39M | -$214.94M |
| Shares outstanding | 87.86M | 78.23M |
| Cash flow statement | ||
| Operating cash flow | -$64.06M | $134.32M |
| Capital expenditure | $6.64M | $472,000 |
| Free cash flow | -$70.70M | $133.84M |
| Investing cash flow | -$13.10M | -$101.59M |
| Financing cash flow | $1.79M | $154.42M |
| Depreciation & amortization | $1.03M | $848,000 |
| Stock-based compensation | $37.11M | $33.90M |
Free plan shows the latest 2 periods; Pro shows all 19 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.